Pazopanib radio-sensitization of human sarcoma tumors

Area of Science:

• Oncology
• Radiation Oncology
• Cancer Biology

Background:

• Host microenvironmental factors significantly influence tumor response to single high dose radiation therapy (SDRT).
• Microvascular endothelial damage is a critical regulator of tumor cell lethality following SDRT.
• Acid Sphingomyelinase (ASMase) activation in the endothelium is essential for tumor cure after SDRT, mediating ceramide-induced apoptosis and microvascular dysfunction.

Purpose of the Study:

• To investigate the efficacy of combining SDRT with Pazopanib, a short-acting anti-angiogenic agent, in xenograft models of human sarcoma.
• To determine if Pazopanib enhances SDRT-induced Acid Sphingomyelinase (ASMase) activity and endothelial dysfunction.
• To assess the impact of Pazopanib and SDRT timing on tumor response and cure.

Main Methods:

• Two human sarcoma xenograft models were used.
• Tumor response to SDRT was evaluated following pre-treatment with a single dose of Pazopanib.
• Acid Sphingomyelinase (ASMase) activity and endothelial dysfunction were assessed in vitro and in vivo.
• The timing of Pazopanib administration relative to SDRT was investigated.

Main Results:

• Pre-treatment with Pazopanib significantly increased SDRT-induced ASMase activity and endothelial dysfunction.
• The combination therapy enhanced tumor cure in both sarcoma models.
• The therapeutic effect was critically dependent on the timing of Pazopanib administration relative to SDRT.
• The observed mechanism of action was consistent with that of anti-VEGF/VEGFR2 antibodies.

Conclusions:

• Pazopanib, when combined with SDRT, can shift the therapeutic response towards tumor cure in sarcoma.
• The timing of Pazopanib administration is crucial for maximizing its synergistic effect with SDRT.
• This combination strategy holds significant potential for clinical trial development in sarcoma patients treated with SDRT.